There have been a spate of recent Op-Eds and items related to the decision the FDA has to approve, or not, this Alzheimer anti-amyloid monoclonal antibody therapy.
An advocacy group, Us Against Alzheimers, has been pushing for approval, Feb 23, saying the med may provide more time to patients.
NYT Op-Ed May 28 by two dementia academic doctors: “People Want An Alzheimer’s Drug. This Isn’t The One” [might be behind a paywall]
From a biotech industry newsletter, June 4:
From STATnews, June 4:
A landmark Alzheimer’s drug approval would likely deepen racial inequities in dementia care
And
Aducanumab for AD…..what if? Thought experiment by Dr. J. Karlawish